- Home
- CNOBP vs KLTOW Comparison
CNOBP vs KLTOW Comparison
Compare CNOBP & KLTOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNOBP | KLTOW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 493 | 3 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | CNOBP | KLTOW |
|---|---|---|
| Price | $24.23 | $0.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | N/A |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | N/A |
| 52 Week High | N/A | N/A |
Technical Indicators
Market Signals| Indicator | CNOBP | KLTOW |
|---|---|---|
| Relative Strength Index (RSI) | 57.81 | 44.16 |
| Support Level | $24.03 | $0.13 |
| Resistance Level | $24.24 | $0.15 |
| Average True Range (ATR) | 0.11 | 0.02 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 96.74 | 11.61 |
Price Performance
Historical ComparisonAbout CNOBP ConnectOne Bancorp Inc.
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental and consumer wages.
About KLTOW Klotho Neurosciences Inc. Warrant
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.